Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Base Study + First Extension: Odanacatib 50 mg OW	378	8,043
Total, all-cause mortality	Base Study + First Extension: Placebo	327	8,028
Total, all-cause mortality	Second Extension: Odanacatib 50 mg OW	86	3,144
Total, all-cause mortality	Second Extension: Odanacatib 50 mg OW (Placebo)	39	2,309
Total, other adverse events	Base Study + First Extension: Odanacatib 50 mg OW	5,659	8,043
Total, other adverse events	Base Study + First Extension: Placebo	5,624	8,028
Total, other adverse events	Second Extension: Odanacatib 50 mg OW	311	3,144
Total, other adverse events	Second Extension: Odanacatib 50 mg OW (Placebo)	209	2,309
Total, serious adverse events	Base Study + First Extension: Odanacatib 50 mg OW	2,441	8,043
Total, serious adverse events	Base Study + First Extension: Placebo	2,446	8,028
Total, serious adverse events	Second Extension: Odanacatib 50 mg OW	508	3,144
Total, serious adverse events	Second Extension: Odanacatib 50 mg OW (Placebo)	376	2,309

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00529373/event-totals